Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GUCY1B2 | O75343 | 12/20 | 0.41 |
| ▸ | GUCY1A2 | P33402 | 12/20 | 0.41 |
| ▸ | GUCY1A1 | Q02108 | 12/20 | 0.41 |
| ▸ | GUCY1B1 | Q02153 | 12/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664140 | 0.91 | GUCY1B2 (0.48) | MAPK1SMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL15663756 | 0.90 | SMN1; SMN2 (0.45) | MAPK1SMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL17224948 | 0.89 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15630775 | 0.86 | MAPK1 (0.50) | MAPK1SMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL15663898 | 0.83 | MAPK1 (0.51) | MAPK1SMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL15630778 | 0.83 | SMN1; SMN2 (0.60) | SMN1; SMN2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15812415 | 0.83 | SMN1; SMN2 (0.42) | MAPK1SMN1; SMN2HCRTR1TP53MAPT | |
| SCHEMBL17224951 | 0.82 | GUCY1B2 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15663883 | 0.81 | GUCY1B2 (0.48) | SMN1; SMN2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15664000 | 0.81 | GUCY1B2 (0.49) | MAPK1SMN1; SMN2HCRTR1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137463-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-08 | — | — | EP | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-02 | — | — | US | disclosed |
| WO-2015165930-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015165930-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057958-A1 | ENANTIOMERS OF THE N-(2-AMINO-5-FLUORO-2-METHYLPENTYL)-8-[(2,6-DIFLUOROBENZYL)OXY]-2-METHYLIMIDAZO[1,2-A]PYRIDINE-3-CARBOXAMIDE, AS WELL AS OF THE DI- AND TRIFLUORO DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | AADAC, TNNT2, TNNI3 | MAPK1 2263/4885SMN1; SMN2 1771/4885HCRTR1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.